Abstracts tagged "fibrosis"

Abstract Number: 2677 • 2017 ACR/ARHP Annual Meeting
Impact of Rheumatologic Evaluation and Serologic Testing on Patients with Fibrotic Interstitial Lung Disease: A Single Center Retrospective Experience
Lindsey A. MacFarlane¹ and Paul F. Dellaripa², ¹Rheumatology, Brigham & Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women’s Hospital, Boston, MD
Background/Purpose: The evaluation of patients who develop interstitial lung disease (ILD) includes an assessment for underlying rheumatic disease or connective tissue disease (CTD). Delineating a…
Abstract Number: 766 • 2017 ACR/ARHP Annual Meeting
Increased Plasma Levels of Hsp90 Are Associated with More Severe Organ Involvement in Patients with Systemic Sclerosis
Hana Storkanova¹, Sabina Oreska¹, Maja Spiritovic^1,2, Karel Pavelka¹, Jiri Vencovsky¹, Jörg Distler³, Ladislav Senolt¹, Radim Becvar¹ and Michal Tomcik¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Our previous study demonstrated that Heat shock protein 90 (Hsp90) is overexpressed in the skin of patients with systemic sclerosis (SSc), in cultured SSc…
Abstract Number: 2776 • 2017 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells in Systemic Fibrosis: Pathogenic Role in Bleomycin-Induced Fibrosis Model and Correlation with Disease in Patients with Systemic Sclerosis
Suzanne Kafaja¹, Isela Valera², Anagha Divekar³, Rajan Saggar⁴, Dinesh Khanna⁵, Daniel E. Furst⁶ and Ram R. Singh⁷, ¹Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ²Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ³Biolegend, Sa Diego, CA, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
Background/Purpose: Fibrosis is the end-result of most inflammatory conditions, but its pathogenesis remains unclear. Studies in patients and animal models suggest a role for T-cells…
Abstract Number: 768 • 2017 ACR/ARHP Annual Meeting
A Positive Feedback Loop between Estrogen and IL-6 Leads to Fibrosis in Human Skin
DeAnna Baker Frost¹ and Carol A. Feghali-Bostwick², ¹Medicine, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology and Immunology, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, United States, Charleston, SC
Background/Purpose: Systemic Sclerosis (SSc) is a disease characterized by an increase in the synthesis of extracellular matrix (ECM) components in various organs, including the skin,…
Abstract Number: 2926 • 2017 ACR/ARHP Annual Meeting
Fucosyltransferase-1 Mediates Macrophage Driven Myofibroblast Differentiation and TGF-β Signaling in Systemic Sclerosis and Bleomycin-Induced Fibrosis
W. Alexander Stinson¹, Ellen Cealey¹, Pei-Suen Tsou¹, Ray A. Ohara¹, Yuxuan Du², Jonatan Hervoso¹, Nicholas Lepore¹, Sarah Arwani¹, Dinesh Khanna¹, David A. Fox¹ and M. Asif Amin¹, ¹Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ²Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, MI
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by dysregulated fibrosis of the skin. During fibrosis, macrophage release of transforming growth factor (TGF-β)…
Abstract Number: 774 • 2017 ACR/ARHP Annual Meeting
The αV Integrin Inhibitor Abituzumab Inhibits Myofibroblast Differentiation
Eileen Samy¹, Yin Wu¹, Georgianna Higginbotham², Roland Grenningloh² and Daigen Xu², ¹TIP Immunology, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ²EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA
Background/Purpose: Scleroderma is a progressive fibrotic multi-organ disease characterized by the hardening and tightening of the skin and connective tissues. TGF-β1 is a potent mediator…
Abstract Number: 2929 • 2017 ACR/ARHP Annual Meeting
WNT5A Promotes Tissue Fibrosis By Wnt/PCP-Dependent Activation of Latent TGF-β
Chih-Wei Chen¹, Thuong Trinh-Minh², Neng-Yu Lin², Yun Zhang³, Florian Groeber⁴, Christian Beyer⁵, Georg Schett⁶ and Jörg Distler⁷, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 and Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ⁴Translational Center Würzburg, Fraunhofer Ins. IGB, Würzburg, Germany, ⁵Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ⁶Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
Background/Purpose: Canonical Wnt/β-catenin signaling has emerged as a core pathway of fibrosis. They role of non-canonical Wnt signaling, however, has not been systematically studied. In…
Abstract Number: 1679 • 2017 ACR/ARHP Annual Meeting
Different Cut-Offs for Renal Resistive Index Reflect Renal and Other Organ Involvement and Predict Worsening in SSc Patients
Cosimo Bruni¹, Vanessa Maestripieri², Giulia Tesei³, Marco Chiostri⁴, Serena Guiducci³, Silvia Bellando-Randone¹, Maria Boddi⁴ and Marco Matucci-Cerinic³, ¹Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ²Department of Internal Medicine, Division of Medicine for Care Complexity III, University of Florence, Florence, Italy, ³Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ⁴Department of Heart and Vessels, Division of Cardiology I, University of Florence, Florence, Italy
Background/Purpose: Renal Resistive Index (RRI), measured by Doppler ultrasound, reflects changes in both renal vascular and tubular-interstitial compartments and systemic vascular compliance related to age…
Abstract Number: 1688 • 2017 ACR/ARHP Annual Meeting
Stem Cell-Enriched Lipotransfer Substantially Improves Measures of Appearance and Function Due to Facial Fibrosis in Systemic Sclerosis
Aurora Almadori^1,2, Caroline Ryan², Michelle Griffin³, Esther Hansen⁴, Christopher Denton⁵ and Peter Butler^6,7, ¹Plastic Surgery, Royal Free NHS Foundation Trust London Hospital, London, United Kingdom, ²Division of Surgery and Interventional Science, UCL, London, United Kingdom, ³Division of Surgery and Interventional Sclemce, UCL, london, United Kingdom, ⁴Clinical Psychology, Plastic Surgery, Royal Free London NHS Foundation Trust Hospital, London, United Kingdom, ⁵Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ⁶Plastic Surgery, Royal Free London NHS Foundation Trust Hospital, London, United Kingdom, ⁷Division of Surgery and Interveitional Science, UCL, London, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is characterised by fibrosis of the skin and underlying connective tissue structures, together with localised loss of subcutaneous fat. Oro-facial fibrosis…
Abstract Number: 811 • 2016 ACR/ARHP Annual Meeting
Basophils Are Activated and Stimulate Both B Cells and Fibroblasts in Systemic Sclerosis
Benjamin Chaigne¹, Nicolas Dumoitier², Alexis Regent¹, Benjamin Terrier³, Jonathan London², Matthieu Groh¹, Nathalie Thieblemont⁴ and Luc Mouthon⁵, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ³Internal Medicine, Cochin Hospital, Paris, France, ⁴Inserm U1016, Paris, France, ⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a rare multisystem connective tissue disease characterized by skin and internal organs fibrosis and vascular abnormalities, along with the presence…
Abstract Number: 2355 • 2016 ACR/ARHP Annual Meeting
Histology of Bone Marrow Lesions in Osteoarthritis: A Systematic Literature Review
S. van Beest¹, F.P.B. Kroon¹, W. Damman¹, J.W. Schoones², A. Ioan-Facsinay¹ and M. Kloppenburg³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Walaeus Library, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology and Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Bone marrow lesions (BMLs) are of high interest in osteoarthritis for their association with pain and structural progression. They are characterized on magnetic resonance…
Abstract Number: 812 • 2016 ACR/ARHP Annual Meeting
Monocytes/Neurotrophins/Myofibroblasts As a Novel Axis in Systemic Sclerosis
Michal Rudnik¹, Mara Stellato¹, Elena Pachera¹, Rucsandra Dobrota¹, Britta Maurer¹, Joerg C. Henes², Karin Klingel³, Karl Sotlar⁴, Przemyslaw Blyszczuk⁵, Oliver Distler¹ and Gabriela Kania¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ³Department of Molecular Pathology, University Hospital Tuebingen, Tuebingen, Germany, ⁴Institute of Pathology, Ludwig Maximilians University, Munich, Germany, ⁵Cardioimmunology, Center of Molecular Cardiology, University of Zurich, 8952 Schlieren, Switzerland
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease, which is characterized by inflammation, fibrosis and vasculopathy in multiple organs, mainly in the lung, heart and…
Abstract Number: 2422 • 2016 ACR/ARHP Annual Meeting
Cyclic Amp, Erk5, and Transdifferentiation of Cardiac Fibroblasts in the Pathogenesis of Autoimmune Congenital Heart Block
Androo Markham¹, Sara Rasmussen², Miki Blumenberg³, Robert M Clancy² and Jill P. Buyon¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Dermatology, NYU School of Medicine, New York, NY
Background/Purpose: Maternal autoantibodies (Ab) reactive with the Ro/La ribonucleoprotein complex are associated with the development of cardiac injury in a fetus passively exposed to these…
Abstract Number: 823 • 2016 ACR/ARHP Annual Meeting
A Phase 2 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness in Subjects with Systemic Sclerosis with Interstitial Lung Disease
Vivien Hsu¹, Christopher P.Denton², Robyn T. Domsic³, Daniel E. Furst⁴, Maureen Rischmueller⁵, Marina Stanislav⁶, Virginia D. Steen⁷, Douglas Hough⁸, Shimon Korish⁹, Alyse Cooper¹⁰, Peter H. Schafer¹¹ and Suktae Choi¹², ¹Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ²Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ³Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵University of Adelaide, Adelaide, Australia, ⁶Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, ⁷Rheumatology, Georgetown University Medical Center, Washington, DC, ⁸Clinical Research, Celgene Corporation, Warren, NJ, ⁹33 Technology Drive, Celgene Corporation, Warren, NJ, ¹⁰Immunology & Inflammation, Clinical Research, Celgene Corporation, Summit, NJ, ¹¹Department of Translational Development, Celgene Corporation, Summit, NJ, ¹²Biostatistics, Celgene Corporation, Summit, NJ
Background/Purpose: Pomalidomide (POM) is an IMiD compound, structurally similar to thalidomide. POM binds to cereblon and facilitates Ikaros and Aiolos degradation, resulting in immunomodulation of…
Abstract Number: 2507 • 2016 ACR/ARHP Annual Meeting
Assessment of Liver Fibrosis Using Transient Elastography in Patients with Rheumatoid Arthritis Exposed to Long Term Methotrexate
Min Kyung Chung¹, Seo Hwa Kim², Haneul Kim¹, Jung Hee Koh¹, Jennifer Lee³, Seung-Ki Kwok⁴, Ji Hyeon Ju⁵ and Sung-Hwan Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ²Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ⁴[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Methotrexate (MTX) has been recommended for the first line therapy of rheumatoid arthritis (RA), either alone or in combination with other DMARDs such as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].